Senseonics Holdings (SENS) Tops Q4 EPS by 22c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results
March 1, 2022 4:05 PM ESTGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2021.
Recent Highlights & Accomplishments:
Received approval from the Food and Drug Administration (FDA) for the Eversense® E3 CGM System, offering patients: Fully implantable third generation sensor, with proprietary sacrificial boronic acid (SBA) technology to enhance sensor longevity, demonstrating a mean... More